NORDIC NANOVECTOR AS: EXTRAORDINARY GENERAL MEETING ON 12 NOVEMBER 2014
The Board of Directors of Nordic Nanovector AS has resolved to call for an extraordinary general meeting (EGM) to be held on 12 November 2014 at 15:00 (CET) in the Company’s offices at Kjelsåsveien 168 B, 4th floor.
On the agenda for the EGM is inter alia conversion of the Company into a public limited company, Board and nomination committee elections and remuneration, instructions for the nomination committee and amendments to the Articles of Association.
The EGM notice with enclosures is sent to the shareholders today and is also attached to this press release.
Luigi Costa, Chief Executive Officer
Cell: (+41) 79 124 8601
Tone Kvåle, Chief Financial Officer
Cell: (+47) 91 51 95 76
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).